Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Govt’s All-Generation Social Security Panel Compiles Interim Report, No Mention of OTC-Like Drugs
A key government panel on December 19 drew up an interim report on the direction of reforms to create a “social security system benefiting all generations” envisaged by Prime Minister Shinzo Abe, but for now, the paper had no mention…
To read the full story
Related Article
- Final Report from Govt’s All-Generation Social Security Council to Be Delayed until Year-End
May 26, 2020
- Course of Govt’s “All-Generation” Social Security Reform Could Impact Pharma
December 5, 2019
- “All-Generation” Panel Cites Coverage of OTC-Like Drugs as Policy Issue
November 27, 2019
- Japan Launches Panel to Discuss “Social Security for All Generations”
September 24, 2019
REGULATORY
- Officer Replacement Orders a “Last Resort” under PMD Act: MHLW Official
September 18, 2026
- Japan Panel Sees No Scientific Objection to Capvaxive NIP Addition
September 18, 2026
- Tavneos Blue Letter Action “Too Slow,” MHLW Panel Member Says
September 18, 2026
- Takaichi Tasks Ueno with Charting Growth Strategy for Drug Innovation
September 18, 2026
- Japan HIV, AIDS Cases Rise in H1 after 2025 Lows
September 18, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…